m6A-centered Disease Response Information
General Information of the Disease (ID: M6ADIS0059)
Name |
Colorectal cancer
|
||||
---|---|---|---|---|---|
ICD |
ICD-11: 2B91
|
Full List of Target Gene(s) of This m6A-centered Disease Response
Arrestin domain-containing protein 4 (ARRDC4)
In total 2 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [1] | |||
Response Summary | Knockdown of METTL14 significantly enhanced Arrestin domain-containing protein 4 (ARRDC4) mRNA stability relying on the "reader" protein YHTDF2 dependent manner in colorectal cancer. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 14 (METTL14) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | mRNA surveillance pathway | hsa03015), RNA degradation | ||
Cell Process | RNA stability | |||
In-vitro Model | SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
RKO | Colon carcinoma | Homo sapiens | CVCL_0504 | |
NCM460 | Normal | Homo sapiens | CVCL_0460 | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
HCT 15 | Colon adenocarcinoma | Homo sapiens | CVCL_0292 | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
In-vivo Model | Equal amount of HCT116 cells (2 × 106) stably expression of relevant plasmids was injected into the right flank of mice, tumor bulks was monitored once a week after injection and volumes were counted as 0.5 × a2 × b (a and b respectively indicated short and long diameter of tumor). | |||
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene | [1] | |||
Response Summary | Knockdown of METTL14 significantly enhanced Arrestin domain-containing protein 4 (ARRDC4) mRNA stability relying on the "reader" protein YTHDF2 dependent manner in colorectal cancer. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | mRNA surveillance pathway | hsa03015), RNA degradation | ||
Cell Process | RNA stability | |||
In-vitro Model | SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
RKO | Colon carcinoma | Homo sapiens | CVCL_0504 | |
NCM460 | Normal | Homo sapiens | CVCL_0460 | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
HCT 15 | Colon adenocarcinoma | Homo sapiens | CVCL_0292 | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
In-vivo Model | Equal amount of HCT116 cells (2 × 106) stably expression of relevant plasmids was injected into the right flank of mice, tumor bulks was monitored once a week after injection and volumes were counted as 0.5 × a2 × b (a and b respectively indicated short and long diameter of tumor). | |||
ATP-dependent translocase ABCB1 (ABCB1)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [2] | |||
Response Summary | IGF2BP3, directly bound to the m6A-modified region of ATP-dependent translocase ABCB1 (ABCB1) mRNA, thereby promoting the stability and expression of ABCB1 mRNA. The expression of IGF2BP3 and ABCB1 was strongly correlated with DOX sensitivity. Targeting IGF2BP3 was an important chemotherapeutic strategy for preventing MDR development in colorectal cancer. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Responsed Drug | Doxil | Approved | ||
Target Regulator | Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | ABC transporters | hsa02010 | ||
Cell Process | RNA stability | |||
In-vitro Model | DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
HCT 15 | Colon adenocarcinoma | Homo sapiens | CVCL_0292 | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
SW1463 | Rectal adenocarcinoma | Homo sapiens | CVCL_1718 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
In-vivo Model | HCT8/T xenografts derived from shNC or shIGF2BP3-1 HCT8/T cells were established through subcutaneous inoculation of cells (6×106) into nude mice. | |||
C-X-C motif chemokine 10 (CXCL10)
In total 2 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [3] | |||
Response Summary | In colorectal cancer, Mettl3- or Mettl14-deficient tumors increased cytotoxic tumor-infiltrating CD8+ T cells and elevated secretion of IFN-gamma, Cxcl9, and C-X-C motif chemokine 10 (Cxcl10) in tumor microenvironment in vivo. Mechanistically, Mettl3 or Mettl14 loss promoted IFN-gamma-Stat1-Irf1 signaling through stabilizing the Stat1 and Irf1 mRNA via Ythdf2. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Down regulation | |||
Pathway Response | PD-L1 expression and PD-1 checkpoint pathway in cancer | hsa05235 | ||
Cell Process | Immunity | |||
In-vitro Model | CT26 | Mouse colon adenocarcinoma | Mus musculus | CVCL_7254 |
B16-GM-CSF (B16-GM-CSF cell line was a kind gift from Drs. Glenn Dranoff and Michael Dougan (Dana-Farber/Harvard Cancer Center)) | ||||
B16-F10 | Mouse melanoma | Mus musculus | CVCL_0159 | |
In-vivo Model | 2 × 106 CT26 cells with knockout of Mettl3, Mettl14, Mettl3/Stat1, Mettl3/Irf1, Mettl14/Stat1, or Mettl14/Irf1 and control were suspended in 200 uL of PBS/Matrigel (Corning) (1:1) and then subcutaneously inoculated into flank of each mouse. | |||
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene | [3] | |||
Response Summary | In colorectal cancer, Mettl3- or Mettl14-deficient tumors increased cytotoxic tumor-infiltrating CD8+ T cells and elevated secretion of IFN-gamma, Cxcl9, and C-X-C motif chemokine 10 (Cxcl10) in tumor microenvironment in vivo. Mechanistically, Mettl3 or Mettl14 loss promoted IFN-gamma-Stat1-Irf1 signaling through stabilizing the Stat1 and Irf1 mRNA via Ythdf2. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 14 (METTL14) | WRITER | ||
Target Regulation | Down regulation | |||
Pathway Response | PD-L1 expression and PD-1 checkpoint pathway in cancer | hsa05235 | ||
Cell Process | Immunity | |||
In-vitro Model | CT26 | Mouse colon adenocarcinoma | Mus musculus | CVCL_7254 |
B16-GM-CSF (B16-GM-CSF cell line was a kind gift from Drs. Glenn Dranoff and Michael Dougan (Dana-Farber/Harvard Cancer Center)) | ||||
B16-F10 | Mouse melanoma | Mus musculus | CVCL_0159 | |
In-vivo Model | 2 × 106 CT26 cells with knockout of Mettl3, Mettl14, Mettl3/Stat1, Mettl3/Irf1, Mettl14/Stat1, or Mettl14/Irf1 and control were suspended in 200 uL of PBS/Matrigel (Corning) (1:1) and then subcutaneously inoculated into flank of each mouse. | |||
C-X-C motif chemokine 9 (CXCL9)
In total 2 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [3] | |||
Response Summary | In colorectal cancer, Mettl3- or Mettl14-deficient tumors increased cytotoxic tumor-infiltrating CD8+ T cells and elevated secretion of IFN-gamma, C-X-C motif chemokine 9 (Cxcl9), and Cxcl10 in tumor microenvironment in vivo. Mechanistically, Mettl3 or Mettl14 loss promoted IFN-gamma-Stat1-Irf1 signaling through stabilizing the Stat1 and Irf1 mRNA via Ythdf2. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Down regulation | |||
Pathway Response | PD-L1 expression and PD-1 checkpoint pathway in cancer | hsa05235 | ||
Cell Process | Immunity | |||
In-vitro Model | CT26 | Mouse colon adenocarcinoma | Mus musculus | CVCL_7254 |
B16-GM-CSF (B16-GM-CSF cell line was a kind gift from Drs. Glenn Dranoff and Michael Dougan (Dana-Farber/Harvard Cancer Center)) | ||||
B16-F10 | Mouse melanoma | Mus musculus | CVCL_0159 | |
In-vivo Model | 2 × 106 CT26 cells with knockout of Mettl3, Mettl14, Mettl3/Stat1, Mettl3/Irf1, Mettl14/Stat1, or Mettl14/Irf1 and control were suspended in 200 uL of PBS/Matrigel (Corning) (1:1) and then subcutaneously inoculated into flank of each mouse. | |||
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene | [3] | |||
Response Summary | In colorectal cancer, Mettl3- or Mettl14-deficient tumors increased cytotoxic tumor-infiltrating CD8+ T cells and elevated secretion of IFN-gamma, C-X-C motif chemokine 9 (Cxcl9), and Cxcl10 in tumor microenvironment in vivo. Mechanistically, Mettl3 or Mettl14 loss promoted IFN-gamma-Stat1-Irf1 signaling through stabilizing the Stat1 and Irf1 mRNA via Ythdf2. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 14 (METTL14) | WRITER | ||
Target Regulation | Down regulation | |||
Pathway Response | PD-L1 expression and PD-1 checkpoint pathway in cancer | hsa05235 | ||
Cell Process | Immunity | |||
In-vitro Model | CT26 | Mouse colon adenocarcinoma | Mus musculus | CVCL_7254 |
B16-GM-CSF (B16-GM-CSF cell line was a kind gift from Drs. Glenn Dranoff and Michael Dougan (Dana-Farber/Harvard Cancer Center)) | ||||
B16-F10 | Mouse melanoma | Mus musculus | CVCL_0159 | |
In-vivo Model | 2 × 106 CT26 cells with knockout of Mettl3, Mettl14, Mettl3/Stat1, Mettl3/Irf1, Mettl14/Stat1, or Mettl14/Irf1 and control were suspended in 200 uL of PBS/Matrigel (Corning) (1:1) and then subcutaneously inoculated into flank of each mouse. | |||
Catenin beta-1 (CTNNB1/Beta-catenin)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [4] | |||
Response Summary | Silencing YTHDF1 significantly inhibited Wnt/Catenin beta-1 (CTNNB1/Beta-catenin) pathway activity in Colorectal cancer cells. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | YTH domain-containing family protein 1 (YTHDF1) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | Wnt signaling pathway | hsa04310 | ||
Signaling pathways regulating pluripotency of stem cells | hsa04550 | |||
Cell Process | Cell Tumorigenicity | |||
In-vitro Model | NCM460 | Normal | Homo sapiens | CVCL_0460 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
In-vivo Model | 1 × 105 parental HT29-shNC cells, HT29-shYTHDF1 cells, HT29-shNC colonospheres, and HT29-shYTHDF1 colonospheres were inoculated subcutaneously into the left inguinal folds of the nude mice. | |||
Class E basic helix-loop-helix protein 41 (BHLHE41)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [5] | |||
Response Summary | METTL3 promoted Class E basic helix-loop-helix protein 41 (BHLHE41) expression in m6A-dependent manner, which subsequently induced CXCL1 transcription to enhance MDSC migration in vitro. METTL3 as a potential therapeutic target for CRC immunotherapy whose inhibition reverses immune suppression through m6A-BHLHE41-CXCL1 axis. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | Cytokine-cytokine receptor interaction | hsa04060 | ||
Chemokine signaling pathway | hsa04062 | |||
Cell Process | Cell immunity | |||
Cell growth | ||||
Cell migration | ||||
In-vitro Model | CT26 | Mouse colon adenocarcinoma | Mus musculus | CVCL_7254 |
MC-38 | Mouse colon adenocarcinoma | Mus musculus | CVCL_B288 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
In-vivo Model | METTL3 knockout or control CT26 and MC38 cells were injected subcutaneously into the dorsal flank of each 4- to 6-week-old male immunocompetent BALB/c and C57BL/6 mice, respectively. Anti-Gr-1 (BE0075; Bio-X-Cell, Lebanon, NH) or immunoglobulin (Ig)G isotype control (BE0090, Bio-XCell) was given every other day via intraperitoneal injection (150 ug/mouse). SB-265610 (Tocris, Bristol, UK) or phosphate-buffered saline was administrated through intraperitoneal injections at a dosage of 2 mg/kg per day. Tumor sizes were measured every other day. To establish an orthotopic mouse model of CRC, 5- to 6-week-old male C57BL/6 mice were treated with 1.7% dextran sodium sulfate in drinking water for 5 days, and then allowed to recover for 3 days. After 24 hours of fasting, METTL3 knockout or control MC38 cells suspended in 50 ul of 1 mg/mL Matrigel-phosphate-buffered saline (Corning, Corning, NY) were instilled into the colon lumen of anesthetized mice, coated sparingly with Vaseline. | |||
Cyclic AMP-dependent transcription factor ATF-4 (ATF4)
In total 4 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. ATF4 transcriptionally upregulated DDIT4 to suppress Cyclic AMP-dependent transcription factor ATF-4 (ATF4), which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Responsed Drug | Asparagine inhibitor | Approved | ||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Down regulation | |||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. ATF4 transcriptionally upregulated DDIT4 to suppress Cyclic AMP-dependent transcription factor ATF-4 (ATF4), which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Responsed Drug | Asparagine inhibitor | Approved | ||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 3 Reporting the m6A-centered Disease Response by This Target Gene | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Cyclic AMP-dependent transcription factor ATF-4 (ATF4) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Responsed Drug | Chloroquine | Approved | ||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Down regulation | |||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 4 Reporting the m6A-centered Disease Response by This Target Gene | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Cyclic AMP-dependent transcription factor ATF-4 (ATF4) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Responsed Drug | Meclofenamate sodium | Approved | ||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Down regulation | |||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
E3 ubiquitin-protein ligase SIAH1 (SIAH1)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [7] | |||
Response Summary | The RP11/hnRNPA2B1/mRNA complex accelerated the mRNA degradation of two E3 ligases, E3 ubiquitin-protein ligase SIAH1 (SIAH1) and Fbxo45, and subsequently prevented the proteasomal degradation of Zeb1. m6A can regulate the expression of RP11, further, RP11 regulated Siah1-Fbxo45/Zeb1 was involved in the development of Colorectal cancer. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) | READER | ||
Target Regulation | Down regulation | |||
Pathway Response | Proteasome | hsa03050 | ||
Cell Process | Proteasomal degradation | |||
In-vitro Model | DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 |
HCT 15 | Colon adenocarcinoma | Homo sapiens | CVCL_0292 | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
RKO | Colon carcinoma | Homo sapiens | CVCL_0504 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
In-vivo Model | HCT-15 RP11 stable overexpression or control cells (2 × 106 per mouse) diluted in 100 uL normal medium + 100 uL Matrigel (BD Biosciences) were subcutaneously injected into immunodeficient mice to investigate tumour growth. | |||
Ephrin type-A receptor 2 (EphA2)
In total 3 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [8] | |||
Response Summary | Ephrin type-A receptor 2 (EphA2) and VEGFA targeted by METTL3 via different IGF2BP-dependent mechanisms were found to promote vasculogenic mimicry (VM) formation via PI3K/AKT/mTOR and ERK1/2 signaling in CRC. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Pathway Response | PI3K-Akt signaling pathway | hsa04151 | ||
In-vitro Model | SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
NCM460 | Normal | Homo sapiens | CVCL_0460 | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 | |
In-vivo Model | A total of 8 × 106 wild-type (WT) or METTL3-knockdown cells were injected into the dorsal flanks of 6-week-old nude mice. Seven mice were randomly selected to calculate the volume according to the following formula: V = (width2 × length)/2. Mice were euthanized three weeks after injection and tumors removed, weighed, fixed, and embedded for immunohistochemical analysis. | |||
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene | [8] | |||
Response Summary | Ephrin type-A receptor 2 (EphA2) and VEGFA targeted by METTL3 via different IGF2BP3-dependent mechanisms were found to promote vasculogenic mimicry (VM) formation via PI3K/AKT/mTOR and ERK1/2 signaling in CRC. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | PI3K-Akt signaling pathway | hsa04151 | ||
In-vitro Model | SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
NCM460 | Normal | Homo sapiens | CVCL_0460 | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 | |
In-vivo Model | A total of 8 × 106 wild-type (WT) or METTL3-knockdown cells were injected into the dorsal flanks of 6-week-old nude mice. Seven mice were randomly selected to calculate the volume according to the following formula: V = (width2 × length)/2. Mice were euthanized three weeks after injection and tumors removed, weighed, fixed, and embedded for immunohistochemical analysis. | |||
Experiment 3 Reporting the m6A-centered Disease Response by This Target Gene | [8] | |||
Response Summary | Ephrin type-A receptor 2 (EphA2) and VEGFA targeted by METTL3 via different IGF2BP2-dependent mechanisms were found to promote vasculogenic mimicry (VM) formation via PI3K/AKT/mTOR and ERK1/2 signaling in CRC. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | PI3K-Akt signaling pathway | hsa04151 | ||
In-vitro Model | SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
NCM460 | Normal | Homo sapiens | CVCL_0460 | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 | |
In-vivo Model | A total of 8 × 106 wild-type (WT) or METTL3-knockdown cells were injected into the dorsal flanks of 6-week-old nude mice. Seven mice were randomly selected to calculate the volume according to the following formula: V = (width2 × length)/2. Mice were euthanized three weeks after injection and tumors removed, weighed, fixed, and embedded for immunohistochemical analysis. | |||
Ephrin type-B receptor 2 (ERK/EPHB2)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [9] | |||
Response Summary | METTL3 played a tumor-suppressive role in Colorectal cancer cell proliferation, migration and invasion through p38/Ephrin type-B receptor 2 (ERK/EPHB2) pathways, which indicated that METTL3 was a novel marker for CRC carcinogenesis, progression and survival. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Down regulation | |||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
Cell Process | Cell proliferation | |||
Cell migration | ||||
Cell invasion | ||||
In-vitro Model | DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
KM12 | Colon carcinoma | Homo sapiens | CVCL_1331 | |
Epidermal growth factor receptor (EGFR)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [10] | |||
Response Summary | WM_Score correlated highly with the regulation of transcription and post-transcriptional events contributing to the development of colorectal cancer. In response to anti-cancer drugs, WM_Score highly negatively correlated (drug sensitive) with drugs which targeted oncogenic related pathways, such as MAPK, Epidermal growth factor receptor (EGFR), and mTOR signaling pathways, positively correlated (drug resistance) with drugs which targeted in apoptosis and cell cycle. Importantly, the WM_Score was associated with the therapeutic efficacy of PD-L1 blockade, suggesting that the development of potential drugs targeting these "writers" to aid the clinical benefits of immunotherapy. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
VEGF signaling pathway | hsa04370 | |||
mTOR signaling pathway | hsa04150 | |||
PD-L1 expression and PD-1 checkpoint pathway in cancer | hsa05235 | |||
Cell Process | Cell apoptosis | |||
F-box/SPRY domain-containing protein 1 (FBXO45)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [7] | |||
Response Summary | The RP11/hnRNPA2B1/mRNA complex accelerated the mRNA degradation of two E3 ligases, Siah1 and F-box/SPRY domain-containing protein 1 (FBXO45), and subsequently prevented the proteasomal degradation of Zeb1. m6A can regulate the expression of RP11, further, RP11 regulated Siah1-Fbxo45/Zeb1 was involved in the development of Colorectal cancer. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) | READER | ||
Target Regulation | Down regulation | |||
Pathway Response | Proteasome | hsa03050 | ||
Cell Process | Proteasomal degradation | |||
In-vitro Model | DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 |
HCT 15 | Colon adenocarcinoma | Homo sapiens | CVCL_0292 | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
RKO | Colon carcinoma | Homo sapiens | CVCL_0504 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
In-vivo Model | HCT-15 RP11 stable overexpression or control cells (2 × 106 per mouse) diluted in 100 uL normal medium + 100 uL Matrigel (BD Biosciences) were subcutaneously injected into immunodeficient mice to investigate tumour growth. | |||
Forkhead box protein O3 (FOXO3)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [11] | |||
Response Summary | ALKBH5 plays an antitumor role in colorectal cancer by modulating the Forkhead box protein O3 (FOXO3)/miR-21/SPRY2 axis, which not only suggests a regulatory effect between ALKBH5 and FOXO3, but also provides a new therapeutic direction for colorectal cancer. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | RNA demethylase ALKBH5 (ALKBH5) | ERASER | ||
Target Regulation | Down regulation | |||
Pathway Response | FoxO signaling pathway | hsa04068 | ||
In-vitro Model | Caco-2 | Colon adenocarcinoma | Homo sapiens | CVCL_0025 |
FHC | Normal | Homo sapiens | CVCL_3688 | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
G1/S-specific cyclin-E1 (CCNE1)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [12] | |||
Response Summary | METTL3 promotes colorectal cancer proliferation by stabilizing G1/S-specific cyclin-E1 (CCNE1) mRNA in an m6A-dependent manner, representing a promising therapeutic strategy for the treatment of CRC. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | Cell cycle | hsa04110 | ||
Cell Process | Cell proliferation | |||
Arrest cell cycle at G1 phase | ||||
In-vitro Model | HT29 | Colon cancer | Mus musculus | CVCL_A8EZ |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
In-vivo Model | LoVo cells (5 × 106 cells/ 200 uL PBS) stably transfected with METTL3 knockdown lentiviral vector or control vector were respectively injected subcutaneously into the left flank of each mouse. | |||
Glucose transporter type 1 (SLC2A1)
In total 3 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [13] | |||
Response Summary | METTL3 stabilizes HK2 and Glucose transporter type 1 (SLC2A1) (GLUT1) expression in colorectal cancer through an m6A-IGF2BP2/3- dependent mechanism. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | Glycolysis / Gluconeogenesis | hsa00010 | ||
Cell Process | Glucose metabolism | |||
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene | [13] | |||
Response Summary | METTL3 stabilizes HK2 and Glucose transporter type 1 (SLC2A1) (GLUT1) expression in colorectal cancer through an m6A-IGF2BP2/3- dependent mechanism. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | Glycolysis / Gluconeogenesis | hsa00010 | ||
Cell Process | Glucose metabolism | |||
Experiment 3 Reporting the m6A-centered Disease Response by This Target Gene | [14] | |||
Response Summary | METTL3 induced Glucose transporter type 1 (SLC2A1) translation in an m6A-dependent manner, which subsequently promoted glucose uptake and lactate production, leading to the activation of mTORC1 signaling and CRC development. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
In-vivo Model | To generate the Mettl3+/- mice, 2 specific single-guide RNAs (sgRNAs) targeting exon 2 of Mettl3 were used, which resulted in a frameshift mutation and generated a premature stop codon. | |||
Glucose-6-phosphate dehydrogenase (G6PD)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [15] | |||
Response Summary | Targeting FTO significantly suppresses cancer cell growth and enhances chemotherapy sensitivity, which not only mediating the balance of intracellular ROS by regulating Glucose-6-phosphate dehydrogenase (G6PD) expression, but also maintaining genome instability by regulating PARP1 expression. These findings shed light on new molecular mechanisms of CRC development and treatments mediated by m6A modification. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Target Regulation | Up regulation | |||
Pathway Response | Glutathione metabolism | hsa00480 | ||
In-vitro Model | LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
In-vivo Model | For CDX model, nude mice (female, 4-6-week-old) were subcutaneously injected with 5 × 106 HCT116 cells on the both flank. For PDX model, the patient tumors were divided into small pieces and then inoculated on both flank of nude mice. For knockdown FTO mice model, FTO mice model, two weeks after inoculation, the shFTO#3 lenti-virus injected into the tumor for three consecutive days. For combined medication mice model, intraperitoneal injection of Rhein and Olaparib was started one week after inoculation | |||
Hexokinase-2 (HK2)
In total 3 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [13] | |||
Response Summary | METTL3 stabilizes Hexokinase-2 (HK2) and SLC2A1 (GLUT1) expression in colorectal cancer through an m6A-IGF2BP2/3- dependent mechanism. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | Glycolysis / Gluconeogenesis | hsa00010 | ||
Cell Process | Glucose metabolism | |||
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene | [13] | |||
Response Summary | METTL3 stabilizes Hexokinase-2 (HK2) and SLC2A1 (GLUT1) expression in colorectal cancer through an m6A-IGF2BP2/3- dependent mechanism. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | Glycolysis / Gluconeogenesis | hsa00010 | ||
Cell Process | Glucose metabolism | |||
Experiment 3 Reporting the m6A-centered Disease Response by This Target Gene | [16] | |||
Response Summary | KIAA1429 has the potential to promote CRC carcinogenesis by targeting Hexokinase-2 (HK2) via m6A-independent manner, providing insight into the critical roles of m6A in CRC. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulation | Up regulation | |||
Pathway Response | Metabolic pathways | hsa01100 | ||
Glycolysis / Gluconeogenesis | hsa00010 | |||
Cell Process | Glycolysis | |||
In-vitro Model | SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
FHC | Normal | Homo sapiens | CVCL_3688 | |
High mobility group protein HMG-I/HMG-Y (HMGA1)
In total 2 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [17] | |||
Response Summary | LINC00460 is a novel oncogene of colorectal cancer through interacting with IGF2BP2 and DHX9 and bind to the m6A modified High mobility group protein HMG-I/HMG-Y (HMGA1) mRNA to enhance the HMGA1 mRNA stability. The N6-methyladenosine (m6A) modification of HMGA1 mRNA by METTL3 enhanced HMGA1 expression in CRC. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | mRNA surveillance pathway | hsa03015 | ||
Cell Process | mRNA stability | |||
Epithelial-mesenchymal transition | ||||
In-vitro Model | DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 |
FHC | Normal | Homo sapiens | CVCL_3688 | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
In-vivo Model | Groups of HCT116-Luc-shCtrl, HCT116-Luc-shLINC00460, and HCT116-Luc-shLINC00460 + HMGA1 cells (5 × 106) were injected subcutaneously into the flanks of mice correspondingly. | |||
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene | [17] | |||
Response Summary | LINC00460 is a novel oncogene of colorectal cancer through interacting with IGF2BP2 and DHX9 and bind to the m6A modified High mobility group protein HMG-I/HMG-Y (HMGA1) mRNA to enhance the HMGA1 mRNA stability. The N6-methyladenosine (m6A) modification of HMGA1 mRNA by METTL3 enhanced HMGA1 expression in CRC. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | mRNA surveillance pathway | hsa03015 | ||
Cell Process | mRNA stability | |||
Epithelial-mesenchymal transition | ||||
In-vitro Model | DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 |
FHC | Normal | Homo sapiens | CVCL_3688 | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
In-vivo Model | Groups of HCT116-Luc-shCtrl, HCT116-Luc-shLINC00460, and HCT116-Luc-shLINC00460 + HMGA1 cells (5 × 106) were injected subcutaneously into the flanks of mice correspondingly. | |||
Interferon gamma (IFN-gamma)
In total 2 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [3] | |||
Response Summary | In colorectal cancer, Mettl3- or Mettl14-deficient tumors increased cytotoxic tumor-infiltrating CD8+ T cells and elevated secretion of Interferon gamma (IFN-gamma), Cxcl9, and Cxcl10 in tumor microenvironment in vivo. Mechanistically, Mettl3 or Mettl14 loss promoted IFN-gamma-Stat1-Irf1 signaling through stabilizing the Stat1 and Irf1 mRNA via Ythdf2. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Down regulation | |||
Pathway Response | PD-L1 expression and PD-1 checkpoint pathway in cancer | hsa05235 | ||
Cell Process | Immunity | |||
In-vitro Model | CT26 | Mouse colon adenocarcinoma | Mus musculus | CVCL_7254 |
B16-GM-CSF (B16-GM-CSF cell line was a kind gift from Drs. Glenn Dranoff and Michael Dougan (Dana-Farber/Harvard Cancer Center)) | ||||
B16-F10 | Mouse melanoma | Mus musculus | CVCL_0159 | |
In-vivo Model | 2 × 106 CT26 cells with knockout of Mettl3, Mettl14, Mettl3/Stat1, Mettl3/Irf1, Mettl14/Stat1, or Mettl14/Irf1 and control were suspended in 200 uL of PBS/Matrigel (Corning) (1:1) and then subcutaneously inoculated into flank of each mouse. | |||
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene | [3] | |||
Response Summary | In colorectal cancer, Mettl3- or Mettl14-deficient tumors increased cytotoxic tumor-infiltrating CD8+ T cells and elevated secretion of Interferon gamma (IFN-gamma), Cxcl9, and Cxcl10 in tumor microenvironment in vivo. Mechanistically, Mettl3 or Mettl14 loss promoted IFN-gamma-Stat1-Irf1 signaling through stabilizing the Stat1 and Irf1 mRNA via Ythdf2. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 14 (METTL14) | WRITER | ||
Target Regulation | Down regulation | |||
Pathway Response | PD-L1 expression and PD-1 checkpoint pathway in cancer | hsa05235 | ||
Cell Process | Immunity | |||
In-vitro Model | CT26 | Mouse colon adenocarcinoma | Mus musculus | CVCL_7254 |
B16-GM-CSF (B16-GM-CSF cell line was a kind gift from Drs. Glenn Dranoff and Michael Dougan (Dana-Farber/Harvard Cancer Center)) | ||||
B16-F10 | Mouse melanoma | Mus musculus | CVCL_0159 | |
In-vivo Model | 2 × 106 CT26 cells with knockout of Mettl3, Mettl14, Mettl3/Stat1, Mettl3/Irf1, Mettl14/Stat1, or Mettl14/Irf1 and control were suspended in 200 uL of PBS/Matrigel (Corning) (1:1) and then subcutaneously inoculated into flank of each mouse. | |||
Interferon regulatory factor 1 (Irf1)
In total 3 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [3] | |||
Response Summary | In colorectal cancer, Mettl3- or Mettl14-deficient tumors increased cytotoxic tumor-infiltrating CD8+ T cells and elevated secretion of IFN-gamma, Cxcl9, and Cxcl10 in tumor microenvironment in vivo. Mechanistically, Mettl3 or Mettl14 loss promoted IFN-gamma-Stat1-Irf1 signaling through stabilizing the Stat1 and Interferon regulatory factor 1 (Irf1) mRNA via Ythdf2. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Down regulation | |||
Pathway Response | PD-L1 expression and PD-1 checkpoint pathway in cancer | hsa05235 | ||
Cell Process | Immunity | |||
In-vitro Model | CT26 | Mouse colon adenocarcinoma | Mus musculus | CVCL_7254 |
B16-GM-CSF (B16-GM-CSF cell line was a kind gift from Drs. Glenn Dranoff and Michael Dougan (Dana-Farber/Harvard Cancer Center)) | ||||
B16-F10 | Mouse melanoma | Mus musculus | CVCL_0159 | |
In-vivo Model | 2 × 106 CT26 cells with knockout of Mettl3, Mettl14, Mettl3/Stat1, Mettl3/Irf1, Mettl14/Stat1, or Mettl14/Irf1 and control were suspended in 200 uL of PBS/Matrigel (Corning) (1:1) and then subcutaneously inoculated into flank of each mouse. | |||
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene | [3] | |||
Response Summary | In colorectal cancer, Mettl3- or Mettl14-deficient tumors increased cytotoxic tumor-infiltrating CD8+ T cells and elevated secretion of IFN-gamma, Cxcl9, and Cxcl10 in tumor microenvironment in vivo. Mechanistically, Mettl3 or Mettl14 loss promoted IFN-gamma-Stat1-Irf1 signaling through stabilizing the Stat1 and Interferon regulatory factor 1 (Irf1) mRNA via Ythdf2. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 14 (METTL14) | WRITER | ||
Target Regulation | Down regulation | |||
Pathway Response | PD-L1 expression and PD-1 checkpoint pathway in cancer | hsa05235 | ||
Cell Process | Immunity | |||
In-vitro Model | CT26 | Mouse colon adenocarcinoma | Mus musculus | CVCL_7254 |
B16-GM-CSF (B16-GM-CSF cell line was a kind gift from Drs. Glenn Dranoff and Michael Dougan (Dana-Farber/Harvard Cancer Center)) | ||||
B16-F10 | Mouse melanoma | Mus musculus | CVCL_0159 | |
In-vivo Model | 2 × 106 CT26 cells with knockout of Mettl3, Mettl14, Mettl3/Stat1, Mettl3/Irf1, Mettl14/Stat1, or Mettl14/Irf1 and control were suspended in 200 uL of PBS/Matrigel (Corning) (1:1) and then subcutaneously inoculated into flank of each mouse. | |||
Experiment 3 Reporting the m6A-centered Disease Response by This Target Gene | [3] | |||
Response Summary | In colorectal cancer, Mettl3- or Mettl14-deficient tumors increased cytotoxic tumor-infiltrating CD8+ T cells and elevated secretion of IFN-gamma, Cxcl9, and Cxcl10 in tumor microenvironment in vivo. Mechanistically, Mettl3 or Mettl14 loss promoted IFN-gamma-Stat1-Irf1 signaling through stabilizing the Stat1 and Interferon regulatory factor 1 (Irf1) mRNA via Ythdf2. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Down regulation | |||
Pathway Response | PD-L1 expression and PD-1 checkpoint pathway in cancer | hsa05235 | ||
Cell Process | Immunity | |||
In-vitro Model | CT26 | Mouse colon adenocarcinoma | Mus musculus | CVCL_7254 |
B16-GM-CSF (B16-GM-CSF cell line was a kind gift from Drs. Glenn Dranoff and Michael Dougan (Dana-Farber/Harvard Cancer Center)) | ||||
B16-F10 | Mouse melanoma | Mus musculus | CVCL_0159 | |
In-vivo Model | 2 × 106 CT26 cells with knockout of Mettl3, Mettl14, Mettl3/Stat1, Mettl3/Irf1, Mettl14/Stat1, or Mettl14/Irf1 and control were suspended in 200 uL of PBS/Matrigel (Corning) (1:1) and then subcutaneously inoculated into flank of each mouse. | |||
Kinesin-like protein KIF2C (KIF2C)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [18] | |||
Response Summary | The study highlights a robust correlation between the level of cancer stemness and traits related to tumor heterogeneity, including the immune microenvironment, TMB, and the expression of m6A RNA methylation regulatory factors in colorectal cancer cells. A three-gene prognostic signature (PARPBP, KNSTRN, and Kinesin-like protein KIF2C (KIF2C)) was explored together with specific clinical features to construct a nomogram, which was successfully validated in an external cohort. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Krueppel-like factor 4 (KLF4)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [19] | |||
Response Summary | The expression of METTL14 was downregulated in CRC cells and METTL14 could inhibit the metastasis of CRC cells. MeCP2 could bind to METTL14 to coregulate tumor suppressor Krueppel-like factor 4 (KLF4) expression through changing m6 A methylation modification. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 14 (METTL14) | WRITER | ||
Target Regulation | Up regulation | |||
In-vitro Model | SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
In-vivo Model | In vivo, the group of HCT116 cells labeled with luciferase were surgically injected into the spleen of nude mice. After 2 months, the nude mice were subjected to D-luciferin injection and the luciferase signals were monitored and quantified. | |||
Lactate dehydrogenase A (LDHA)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [20] | |||
Response Summary | METTL3 enhances the expression of Lactate dehydrogenase A (LDHA), which catalyzes the conversion of pyruvate to lactate, to trigger glycolysis and 5-FU resistance. METTL3/LDHA axis-induced glucose metabolism is a potential therapy target to overcome 5-FU resistance in CRC cells. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | HIF-1 signaling pathway | hsa04066 | ||
Glycolysis / Gluconeogenesis | hsa00010 | |||
Cell Process | Glycolysis | |||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
In-vivo Model | For subcutaneous transplanted model, sh-control and sh-METTL3 HCT-116/5-FU cells (5 × 106 per mouse) were diluted in 100ul PBS + 100 ul Matrigel (BD Biosciences, San Jose, CA, USA) and injected subcutaneously in the rear flank fat pad of the nude mice. | |||
Metastasis-associated protein MTA1 (MTA1)
In total 2 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [21] | |||
Response Summary | FTO inhibited CRC metastasis both in vitro and in vivo. FTO exerted a tumor suppressive role by inhibiting Metastasis-associated protein MTA1 (MTA1) expression in an m6A-dependent manner. Methylated MTA1 transcripts were recognized by an m6A "reader", insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2), which then stabilized its mRNA. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Target Regulation | Down regulation | |||
Pathway Response | mRNA surveillance pathway | hsa03015 | ||
RNA degradation | hsa03018 | |||
Cell Process | RNA stability | |||
In-vitro Model | SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
RKO | Colon carcinoma | Homo sapiens | CVCL_0504 | |
LS174T | Colon adenocarcinoma | Homo sapiens | CVCL_1384 | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
HCT 15 | Colon adenocarcinoma | Homo sapiens | CVCL_0292 | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 | |
CW-2 | Colon adenocarcinoma | Homo sapiens | CVCL_1151 | |
In-vivo Model | FTO-overexpressing and control cells (2 × 106 suspended in 100 ul PBS) were subcutaneously injected into each mouse. | |||
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene | [21] | |||
Response Summary | FTO inhibited CRC metastasis both in vitro and in vivo. FTO exerted a tumor suppressive role by inhibiting Metastasis-associated protein MTA1 (MTA1) expression in an m6A-dependent manner. Methylated MTA1 transcripts were recognized by an m6A "reader", insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2), which then stabilized its mRNA. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | mRNA surveillance pathway | hsa03015 | ||
RNA degradation | hsa03018 | |||
Cell Process | RNA stability | |||
In-vitro Model | SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
RKO | Colon carcinoma | Homo sapiens | CVCL_0504 | |
LS174T | Colon adenocarcinoma | Homo sapiens | CVCL_1384 | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
HCT 15 | Colon adenocarcinoma | Homo sapiens | CVCL_0292 | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 | |
CW-2 | Colon adenocarcinoma | Homo sapiens | CVCL_1151 | |
In-vivo Model | FTO-overexpressing and control cells (2 × 106 suspended in 100 ul PBS) were subcutaneously injected into each mouse. | |||
Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [10] | |||
Response Summary | WM_Score correlated highly with the regulation of transcription and post-transcriptional events contributing to the development of colorectal cancer. In response to anti-cancer drugs, WM_Score highly negatively correlated (drug sensitive) with drugs which targeted oncogenic related pathways, such as Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1), EGFR, and mTOR signaling pathways, positively correlated (drug resistance) with drugs which targeted in apoptosis and cell cycle. Importantly, the WM_Score was associated with the therapeutic efficacy of PD-L1 blockade, suggesting that the development of potential drugs targeting these "writers" to aid the clinical benefits of immunotherapy. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
VEGF signaling pathway | hsa04370 | |||
mTOR signaling pathway | hsa04150 | |||
PD-L1 expression and PD-1 checkpoint pathway in cancer | hsa05235 | |||
Apoptosis | hsa04210 | |||
Cell Process | Cell apoptosis | |||
Mitogen-activated protein kinase 14 (p38/MAPK14)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [9] | |||
Response Summary | METTL3 played a tumor-suppressive role in Colorectal cancer cell proliferation, migration and invasion through Mitogen-activated protein kinase 14 (p38/MAPK14)/ERK pathways, which indicated that METTL3 was a novel marker for CRC carcinogenesis, progression and survival. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Down regulation | |||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
Cell Process | Cell proliferation | |||
Cell migration | ||||
Cell invasion | ||||
In-vitro Model | DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
KM12 | Colon carcinoma | Homo sapiens | CVCL_1331 | |
Mothers against decapentaplegic homolog 3 (SMAD3)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [22] | |||
Response Summary | METTL3-induced circ1662 promoted colorectal cancer cell invasion and migration by accelerating YAP1 nuclear transport. Circ1662 enhanced CRC invasion and migration depending on YAP1 and Mothers against decapentaplegic homolog 3 (SMAD3). This result implies that circ1662 is a new prognostic and therapeutic marker for CRC metastasis. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Down regulation | |||
Pathway Response | Hippo signaling pathway | hsa04390 | ||
Cell Process | Cell invasion | |||
Cell migration | ||||
In-vitro Model | HEK293T | Normal | Homo sapiens | CVCL_0063 |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
In-vivo Model | BALB/c nude mice (4 weeks old) were acquired from Vital River Laboratory (Beijing, China). HCT116 cells with stable circ1662 expression (2 × 106 in 100 L of PBS) were injected via the tail vein. After 45 days, the mice were sacrificed. The lung metastatic carcinoma specimens were processed into paraffin-embedded sections for subsequent H&E staining and IHC. | |||
Myc proto-oncogene protein (MYC)
In total 4 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [23] | |||
Response Summary | LINRIS blocked K139 ubiquitination of IGF2BP2, maintaining its stability. This process prevented the degradation of IGF2BP2 through the autophagy-lysosome pathway (ALP). The LINRIS-IGF2BP2-Myc proto-oncogene protein (MYC) axis promotes the progression of Colorectal cancer and is a promising therapeutic target. MYC-mediated glycolysis was influenced by the interaction between LINRIS and IGF2BP2. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | Ubiquitin mediated proteolysis | hsa04120 | ||
Glycolysis / Gluconeogenesis | hsa00010 | |||
Cell Process | Autophagy-lysosome pathway | |||
Ubiquitination | ||||
Glycolysis | ||||
In-vitro Model | DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
In-vivo Model | For the orthotopic models, 2 × 106 cells with negative control (NC, sh-NC), sh-1 or sh-2 in 0.5 mL of PBS were subcutaneously injected into the dorsal flank of 2 mice respectively. Then 15 mice were separated into 3 groups (sh-NC, sh-1 and sh-2), of which the tumor pieces were tied to the base of the ceca. The growth of the tumors was monitored every 2 weeks after intraperitoneal injection of D-luciferin with a Xenogen IVIS 100 Bioluminescent Imaging System. | |||
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene | [24] | |||
Response Summary | METTL3 exerted its function through enhancing Myc proto-oncogene protein (MYC) expression, at least partially in an m6A-IGF2BP1-dependent manner. Knockdown of METTL3 suppressed colorectal cancer cell proliferation in vitro and in vivo. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Cell Process | Cell proliferation | |||
In-vitro Model | HEK293T | Normal | Homo sapiens | CVCL_0063 |
Caco-2 | Colon adenocarcinoma | Homo sapiens | CVCL_0025 | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
In-vivo Model | METTL3 stable knockdown or overexpression HCT116 cells were collected and resuspended at a density of 5 × 106 or 3 × 106 cells per 150 uL PBS. | |||
Experiment 3 Reporting the m6A-centered Disease Response by This Target Gene | [25] | |||
Response Summary | miR-96 antagomir could potentially retard the cancerogenesis in colorectal cancer via AMPK-alpha-2-dependent inhibition of FTO and blocking FTO-mediated m6A modification of Myc proto-oncogene protein (MYC). | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Target Regulation | Up regulation | |||
Cell Process | Cell proliferation | |||
Cell apoptosis | ||||
In-vitro Model | HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
In-vivo Model | RC cells SW480 at logarithmic growth phase were prepared into cell suspension with a concentration of about 1 × 107/100 L, which was then injected into the left axilla of nude mice with a 1 ml syringe to establish a subcutaneous mouse xenograft model. Once the tumor volume reached about 50 mm3, the nude mice were injected with miR-96 antagomir or NC antagomir (10 nmol once every 5 days for 5 weeks). After 5 weeks, the mice were euthanized, after which the subcutaneous transplanted tumor was removed, and weighed. | |||
Experiment 4 Reporting the m6A-centered Disease Response by This Target Gene | [26] | |||
Response Summary | GSK3beta inhibited MZF1 expression by mediating FTO-regulated m6A modification of MZF1 and then decreased the proto-oncogene Myc proto-oncogene protein (MYC) expression, thus hampering CRC cell proliferation. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Target Regulation | Down regulation | |||
Pathway Response | Ubiquitin mediated proteolysis | hsa04120 | ||
Cell Process | Cell proliferation | |||
In-vitro Model | SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
In-vivo Model | Twenty-four specific pathogen free female BALB/c nude mice (age: 6 weeks, weight: 15 ~ 18 g) were purchased from Slac Laboratory Animal Co., Ltd., and subcutaneously injected with SW620 cells stably transfected with oe-NC, oe-GSK3-Beta + oe-NC, or oe-GSK3-Beta + oe-c-Myc to establish a subcutaneous xenograft tumour model in nude mice. | |||
Myeloid differentiation primary response protein MyD88 (MYD88)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [27] | |||
Response Summary | RBM15 silencing inhibited the CRC growth and metastasis in vitro and in vivo. RBM15 mediated m6A methylation modification of Myeloid differentiation primary response protein MyD88 (MYD88) mRNA in colorectal cancer cells. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | RNA-binding motif protein 15 (RBM15) | WRITER | ||
Target Regulation | Down regulation | |||
Cell Process | Cell proliferative | |||
Cell invasive | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Myeloid zinc finger 1 (MZF1)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [26] | |||
Response Summary | GSK3beta inhibited Myeloid zinc finger 1 (MZF1) expression by mediating FTO-regulated m6A modification of MZF1 and then decreased the proto-oncogene c-Myc expression, thus hampering CRC cell proliferation. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Target Regulation | Down regulation | |||
Pathway Response | Ubiquitin mediated proteolysis | hsa04120 | ||
Cell Process | Cell proliferation | |||
In-vitro Model | SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
In-vivo Model | Twenty-four specific pathogen free female BALB/c nude mice (age: 6 weeks, weight: 15 ~ 18 g) were purchased from Slac Laboratory Animal Co., Ltd., and subcutaneously injected with SW620 cells stably transfected with oe-NC, oe-GSK3-Beta + oe-NC, or oe-GSK3-Beta + oe-c-Myc to establish a subcutaneous xenograft tumour model in nude mice. | |||
NAD-dependent protein deacetylase sirtuin-1 (SIRT1)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [28] | |||
Response Summary | KIAA1429 increased the expression of NAD-dependent protein deacetylase sirtuin-1 (SIRT1) via regulating its mRNA stability in an m6A-dependent manner. More importantly, in vivo experiment showed that depletion of KIAA1429 significantly inhibited colorectal tumor growth. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Protein virilizer homolog (VIRMA) | WRITER | ||
Target Regulation | Up regulation | |||
In-vitro Model | SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
NCM460 | Normal | Homo sapiens | CVCL_0460 | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
In-vivo Model | 5.0 × 106 SW480 cells (infected with scr or KIAA1429 shRNA) that suspended in 50 ul PBS and mixed with an equal volume of matrigel were subcutaneously injected in a 6-weeks-old male NOD/SCID (The Jackson Laboratory, Stock No: 001303) mice flank. We started measuring tumor size at the indicated times one week after injection. | |||
Neurocalcin-delta (NCALD)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [29] | |||
Response Summary | METTL3?dependent m6A methylation was upregulated in CRC to promote the processing of miR?181d?5p by DGCR8. This led to increased miR?181d?5p expression, which inhibited the 5?FU sensitivity of CRC cells by targeting Neurocalcin-delta (NCALD). | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Responsed Drug | Fluorouracil | Approved | ||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Down regulation | |||
In-vitro Model | HT29 | Colon cancer | Mus musculus | CVCL_A8EZ |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
In-vivo Model | A tumor-bearing model was established by subcutaneously injecting 100 ul HT29 cells (5×106) followed by an intravenous injection of CAFs-derived exosomes (50 ug/mouse every three days) into the tail vein of the mice. An intraperitoneal injection of 5-FU (50 mg/kg, every week) was administered on day 12. | |||
Obg-like ATPase 1 (OLA1)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [30] | |||
Response Summary | The critical modulation network underlying m6A readers stabilizes lncRNAs, and they jointly promote mitochondrial energy metabolism in the pathogenesis of colorectal cancer. N6-methyladenosine reader stabilizes the ZFAS1/OLA1 axis. Thus, direct interaction between the KH3-4 domain of IMP2 and ZFAS1 where IMP2 serves as a reader for m6A-modified ZFAS1 and promotes the RNA stability of ZFAS1 is critical for CRC development. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) | READER | ||
Target Regulation | Up regulation | |||
Cell Process | Warburg effect | |||
Mitochondrial energy metabolism | ||||
In-vitro Model | Caco-2 | Colon adenocarcinoma | Homo sapiens | CVCL_0025 |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
HIEC (Normal intestinal epithelial cells) | ||||
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
RKO | Colon carcinoma | Homo sapiens | CVCL_0504 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
PCNA-interacting partner (PARPBP)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [18] | |||
Response Summary | The study highlights a robust correlation between the level of cancer stemness and traits related to tumor heterogeneity, including the immune microenvironment, TMB, and the expression of m6A RNA methylation regulatory factors in colorectal cancer cells. A three-gene prognostic signature (PCNA-interacting partner (PARPBP), KNSTRN, and KIF2C) was explored together with specific clinical features to construct a nomogram, which was successfully validated in an external cohort. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Poly [ADP-ribose] polymerase 1 (PARP1)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [15] | |||
Response Summary | Targeting FTO significantly suppresses cancer cell growth and enhances chemotherapy sensitivity, which not only mediating the balance of intracellular ROS by regulating G6PD expression, but also maintaining genome instability by regulating Poly [ADP-ribose] polymerase 1 (PARP1) expression. These findings shed light on new molecular mechanisms of CRC development and treatments mediated by m6A modification. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Target Regulation | Up regulation | |||
Pathway Response | Glutathione metabolism | hsa00480 | ||
In-vitro Model | LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
In-vivo Model | For CDX model, nude mice (female, 4-6-week-old) were subcutaneously injected with 5 × 106 HCT116 cells on the both flank. For PDX model, the patient tumors were divided into small pieces and then inoculated on both flank of nude mice. For knockdown FTO mice model, FTO mice model, two weeks after inoculation, the shFTO#3 lenti-virus injected into the tumor for three consecutive days. For combined medication mice model, intraperitoneal injection of Rhein and Olaparib was started one week after inoculation | |||
Programmed cell death 1 ligand 1 (CD274/PD-L1)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [10] | |||
Response Summary | WM_Score correlated highly with the regulation of transcription and post-transcriptional events contributing to the development of colorectal cancer. In response to anti-cancer drugs, WM_Score highly negatively correlated (drug sensitive) with drugs which targeted oncogenic related pathways, such as MAPK, EGFR, and mTOR signaling pathways, positively correlated (drug resistance) with drugs which targeted in apoptosis and cell cycle. Importantly, the WM_Score was associated with the therapeutic efficacy of Programmed cell death 1 ligand 1 (CD274/PD-L1) blockade, suggesting that the development of potential drugs targeting these "writers" to aid the clinical benefits of immunotherapy. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
VEGF signaling pathway | hsa04370 | |||
mTOR signaling pathway | hsa04150 | |||
PD-L1 expression and PD-1 checkpoint pathway in cancer | hsa05235 | |||
Cell Process | Cell apoptosis | |||
Protein crumbs homolog 3 (CRB3)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [31] | |||
Response Summary | m6A and METTL3 levels were substantially elevated in colorectal carcinoma(CRC) tissues, METTL3 knockdown substantially reduced the m6A level of Protein crumbs homolog 3 (CRB3), and inhibited the degradation of CRB3 mRNA to increase CRB3 expression. METTL3 regulated the progression of CRC by regulating the m6A-CRB3-Hippo pathway. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Down regulation | |||
Pathway Response | Hippo signaling pathway | hsa04390 | ||
Cell Process | Cell proliferation | |||
Cell migration | ||||
Cell invasion | ||||
In-vitro Model | FHC | Normal | Homo sapiens | CVCL_3688 |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
Protein sprouty homolog 2 (SPRY2)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [11] | |||
Response Summary | ALKBH5 plays an antitumor role in colorectal cancer by modulating the FOXO3/miR-21/Protein sprouty homolog 2 (SPRY2) axis, which not only suggests a regulatory effect between ALKBH5 and FOXO3, but also provides a new therapeutic direction for colorectal cancer. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | RNA demethylase ALKBH5 (ALKBH5) | ERASER | ||
Target Regulation | Up regulation | |||
Pathway Response | FoxO signaling pathway | hsa04068 | ||
In-vitro Model | Caco-2 | Colon adenocarcinoma | Homo sapiens | CVCL_0025 |
FHC | Normal | Homo sapiens | CVCL_3688 | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
Protein yippee-like 5 (YPEL5)
In total 2 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [32] | |||
Response Summary | METTL3-catalyzed m6A modification in CRC tumorigenesis, wherein it facilitates CRC tumor growth and metastasis through suppressing Protein yippee-like 5 (YPEL5) expression in an m6A-YTHDF2-dependent manner. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Down regulation | |||
In-vitro Model | SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
NCM460 | Normal | Homo sapiens | CVCL_0460 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
In-vivo Model | For the xenograft model, METTL3 stable overexpressed SW620 cells (1 × 107) or control cells were subcutaneously injected into the right axilla of the female anesthetized BALB/C nude mice (4-6 weeks old, 18-20 g, four mice per group), respectively. The body weight and tumor volumes (length × width2 × 0.5) were measured twice a week. After 21 days, all mice were sacrificed and tumors were surgically removed for hematoxylin-eosin (H&E) staining.For the metastasis model, MTTL3 stable overexpressed SW620 cells (1 × 106) or control cells were injected into the exposed spleen of the anesthetized BALB/C nude mice, respectively. After 21 days, liver metastases were carefully detected using a fluorescent stereoscope and embedded for H&E staining. | |||
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene | [32] | |||
Response Summary | METTL3-catalyzed m6A modification in CRC tumorigenesis, wherein it facilitates CRC tumor growth and metastasis through suppressing Protein yippee-like 5 (YPEL5) expression in an m6A-YTHDF2-dependent manner. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Down regulation | |||
In-vitro Model | SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
NCM460 | Normal | Homo sapiens | CVCL_0460 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
In-vivo Model | For the xenograft model, METTL3 stable overexpressed SW620 cells (1 × 107) or control cells were subcutaneously injected into the right axilla of the female anesthetized BALB/C nude mice (4-6 weeks old, 18-20 g, four mice per group), respectively. The body weight and tumor volumes (length × width2 × 0.5) were measured twice a week. After 21 days, all mice were sacrificed and tumors were surgically removed for hematoxylin-eosin (H&E) staining.For the metastasis model, MTTL3 stable overexpressed SW620 cells (1 × 106) or control cells were injected into the exposed spleen of the anesthetized BALB/C nude mice, respectively. After 21 days, liver metastases were carefully detected using a fluorescent stereoscope and embedded for H&E staining. | |||
Putative pituitary tumor-transforming gene 3 protein (PTTG3P)
In total 2 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [33] | |||
Response Summary | In colorectal cancer, n6-methyladenosine (m6A) subunit METTL3 increased PTTG3P expression by influencing its stability, while insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2) could identify Putative pituitary tumor-transforming gene 3 protein (PTTG3P) m6A methylation status and bind to it. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Down regulation | |||
Pathway Response | Hippo signaling pathway | hsa04390 | ||
Cell Process | Cell proliferation and suppression of apoptosis | |||
In-vitro Model | FHC | Normal | Homo sapiens | CVCL_3688 |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
NCM460 | Normal | Homo sapiens | CVCL_0460 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
In-vivo Model | Indicated cells (1 × 107) were subcutaneously injected into 4-week-old male nude mice. Tumor volume was measured every 5 days. | |||
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene | [33] | |||
Response Summary | In colorectal cancer, n6-methyladenosine (m6A) subunit METTL3 increased PTTG3P expression by influencing its stability, while insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2) could identify Putative pituitary tumor-transforming gene 3 protein (PTTG3P) m6A methylation status and bind to it. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | Hippo signaling pathway | hsa04390 | ||
Cell Process | Cell proliferation and suppression of apoptosis | |||
In-vitro Model | FHC | Normal | Homo sapiens | CVCL_3688 |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
NCM460 | Normal | Homo sapiens | CVCL_0460 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
In-vivo Model | Indicated cells (1 × 107) were subcutaneously injected into 4-week-old male nude mice. Tumor volume was measured every 5 days. | |||
RAD51-associated protein 1 (RAD51AP1)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [34] | |||
Response Summary | METTL3 augmented 5?FU?induced DNA damage and overcame 5?FU?resistance in HCT?8R cells, which could be mimicked by inhibition of RAD51-associated protein 1 (RAD51AP1). The present study revealed that the METTL3/RAD51AP1 axis plays an important role in the acquisition of 5?FU resistance in CRC. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Responsed Drug | Fluorouracil | Approved | ||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
In-vitro Model | HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [35] | |||
Response Summary | IGF2BP2 activates the expression of Receptor tyrosine-protein kinase erbB-2 (ERBB2) by recognizing the m6A of YAP, thus affecting the cell cycle of colorectal cancer, inhibiting cell apoptosis, and promoting proliferation. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Responsed Drug | Temozolomide | Approved | ||
Target Regulator | Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | Hippo signaling pathway | hsa04390 | ||
Cell Process | Cell apoptosis | |||
In-vitro Model | HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
In-vivo Model | IGF2BP2 activates the expression of ErbB2 by recognizing the m6A of YAP, thus affecting the cell cycle of CRC, inhibiting cell apoptosis, and promoting proliferation. | |||
Rho guanine nucleotide exchange factor 2 (ARHGEF2)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [36] | |||
Response Summary | YTHDF1 promotes cell growth in CRC cell lines and primary organoids and lung and liver metastasis in vivo. YTHDF1 binds to m6A sites of Rho guanine nucleotide exchange factor 2 (ARHGEF2) messenger RNA, resulting in enhanced translation of ARHGEF2. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | YTH domain-containing family protein 1 (YTHDF1) | READER | ||
Target Regulation | Up regulation | |||
In-vitro Model | SW1116 | Colon adenocarcinoma | Homo sapiens | CVCL_0544 |
RKO | Colon carcinoma | Homo sapiens | CVCL_0504 | |
LS180 | Colon adenocarcinoma | Homo sapiens | CVCL_0397 | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 | |
RNA cytosine C(5)-methyltransferase NSUN2 (NSUN2)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [37] | |||
Response Summary | N6-methyladenosine modification of RNA cytosine C(5)-methyltransferase NSUN2 (NSUN2) modulates cytoplasmic export and stabilizes HMGA2 to promote Colorectal carcinoma LM. By forming a circNSUN2/IGF2BP2/HMGA2 RNA-protein ternary complex in the cytoplasm, circNSUN2 enhances the stability of HMGA2 mRNA to promote CRC metastasis progression. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) | READER | ||
Target Regulation | Up regulation | |||
Cell Process | Cells invasion | |||
In-vitro Model | HEK293T | Normal | Homo sapiens | CVCL_0063 |
DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
SW1116 | Colon adenocarcinoma | Homo sapiens | CVCL_0544 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
In-vivo Model | 2 × 106 cells suspended in 40 uL PBS were injected into the inferior hemispleen into each 6-week-old BALB/c nude mouse. | |||
Serine/threonine-protein kinase mTOR (MTOR)
In total 5 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. ATF4 transcriptionally upregulated DDIT4 to suppress Serine/threonine-protein kinase mTOR (MTOR), which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Responsed Drug | Asparagine inhibitor | Approved | ||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Autophagy | hsa04140 | |||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. ATF4 transcriptionally upregulated DDIT4 to suppress Serine/threonine-protein kinase mTOR (MTOR), which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Responsed Drug | Asparagine inhibitor | Approved | ||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Autophagy | hsa04140 | |||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 3 Reporting the m6A-centered Disease Response by This Target Gene | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Serine/threonine-protein kinase mTOR (MTOR) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Responsed Drug | Chloroquine | Approved | ||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Autophagy | hsa04140 | |||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 4 Reporting the m6A-centered Disease Response by This Target Gene | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Serine/threonine-protein kinase mTOR (MTOR) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Responsed Drug | Meclofenamate sodium | Approved | ||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Autophagy | hsa04140 | |||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 5 Reporting the m6A-centered Disease Response by This Target Gene | [10] | |||
Response Summary | WM_Score correlated highly with the regulation of transcription and post-transcriptional events contributing to the development of colorectal cancer. In response to anti-cancer drugs, WM_Score highly negatively correlated (drug sensitive) with drugs which targeted oncogenic related pathways, such as MAPK, EGFR, and Serine/threonine-protein kinase mTOR (MTOR) signaling pathways, positively correlated (drug resistance) with drugs which targeted in apoptosis and cell cycle. Importantly, the WM_Score was associated with the therapeutic efficacy of PD-L1 blockade, suggesting that the development of potential drugs targeting these "writers" to aid the clinical benefits of immunotherapy. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
VEGF signaling pathway | hsa04370 | |||
mTOR signaling pathway | hsa04150 | |||
PD-L1 expression and PD-1 checkpoint pathway in cancer | hsa05235 | |||
Cell Process | Cell apoptosis | |||
Small kinetochore-associated protein (KNSTRN)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [18] | |||
Response Summary | The study highlights a robust correlation between the level of cancer stemness and traits related to tumor heterogeneity, including the immune microenvironment, TMB, and the expression of m6A RNA methylation regulatory factors in colorectal cancer cells. A three-gene prognostic signature (PARPBP, Small kinetochore-associated protein (KNSTRN), and KIF2C) was explored together with specific clinical features to construct a nomogram, which was successfully validated in an external cohort. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Spectrin beta, non-erythrocytic 2 (SPTBN2)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [38] | |||
Response Summary | Overexpression of LINC01605, regulated by SMYD2-EP300-mediated H3K27ac and H3K4me3 modifications, bound to METTL3 protein to promote m6A modification of Spectrin beta, non-erythrocytic 2 (SPTBN2) mRNA, leading to the development of colorectal cancer. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Cell Process | Cell proliferation and metastasis | |||
Cell apoptosis | ||||
In-vitro Model | Caco-2 | Colon adenocarcinoma | Homo sapiens | CVCL_0025 |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
In-vivo Model | The growth of CC cells in vivo was examined by subcutaneous injection of LoVo cells or Caco-2 cells into NSG mice, while the metastatic ability of cells in vivo by intracardiac injection into mice. | |||
Sprouty-related, EVH1 domain-containing protein 2 (SPRED2)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [39] | |||
Response Summary | METTL3/miR-1246/Sprouty-related, EVH1 domain-containing protein 2 (SPRED2) axis plays an important role in tumor metastasis and provides a new m6A modification pattern in Colorectal cancer development. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
Cell Process | Cell migration and invasion | |||
In-vitro Model | Caco-2 | Colon adenocarcinoma | Homo sapiens | CVCL_0025 |
DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
NCM460 | Normal | Homo sapiens | CVCL_0460 | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
In-vivo Model | The spleen in the upper left lateral abdomen of the anesthetized mice were exposed, 106 cells suspended in 20 uL phosphate-buffered saline (PBS) were injected into the distal tip of the spleen. After injection, replacing the spleen, and closing the incision. | |||
Staphylococcal nuclease domain-containing protein 1 (SND1)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [40] | |||
Response Summary | The colorimetric m6A quantification strategy revealed that Staphylococcal nuclease domain-containing protein 1 (SND1) could alter m6A levels in colorectal cancer cell lines. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Cell Process | RNA stability | |||
In-vitro Model | DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
TNF receptor-associated factor 5 (TRAF5)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [41] | |||
Response Summary | 2-polarized tumor-associated macrophages enabled the oxaliplatin resistance via the elevation of METTL3-mediated m6A modification in Colorectal Cancer cells. Furthermore, they found that TNF receptor-associated factor 5 (TRAF5) contributes to the METTL3-triggered OX resistance in CRC cells. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Responsed Drug | Oxaliplatin | Approved | ||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Down regulation | |||
In-vitro Model | LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
In-vivo Model | HCT-116 cells (3 × 105 cells in 200 uL of saline) were subcutaneously injected into the nude mice to establish xenograft tumors. After 10 days, 10 mg/kg OX or saline was intraperitoneally injected (n = 5 for each group). Si-METTL3 or si-TRAF5 (10 nmol/20 g body weight) was injected twice intratumorally before the start of OX treatment. The mice were examined every 2 days and sacrificed 4 weeks after the OX treatment. | |||
Transcription factor 7-like 2 (TCF7L2)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [42] | |||
Response Summary | MIR100HG and hnRNPA2B1 interact to control the transcriptional activity of Wnt signaling in CRC via regulation of Transcription factor 7-like 2 (TCF7L2) mRNA stability. These findings identified MIR100HG as a potent EMT inducer in CRC that contribute to cetuximab resistance and metastasis by activation of a MIR100HG/hnRNPA2B1/TCF7L2 feedback loop. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Responsed Drug | Cetuximab | Approved | ||
Target Regulator | Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | Wnt signaling pathway | hsa04310 | ||
Cell Process | Epithelial-mesenchymal transition | |||
In-vitro Model | VACO 9P | Rectal adenocarcinoma | Homo sapiens | CVCL_5413 |
T84 | Colon adenocarcinoma | Homo sapiens | CVCL_0555 | |
SW948 | Colon adenocarcinoma | Homo sapiens | CVCL_0632 | |
SW837 | Rectal adenocarcinoma | Homo sapiens | CVCL_1729 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW48 | Colon adenocarcinoma | Homo sapiens | CVCL_1724 | |
SW403 | Colon adenocarcinoma | Homo sapiens | CVCL_0545 | |
SW1116 | Colon adenocarcinoma | Homo sapiens | CVCL_0544 | |
SK-CO-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0626 | |
RKO | Colon carcinoma | Homo sapiens | CVCL_0504 | |
NCI-H716 | Cecum adenocarcinoma | Homo sapiens | CVCL_1581 | |
NCI-H508 | Cecum adenocarcinoma | Homo sapiens | CVCL_1564 | |
LS174T | Colon adenocarcinoma | Homo sapiens | CVCL_1384 | |
LS123 | Colon adenocarcinoma | Homo sapiens | CVCL_1383 | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
LIM2405 | Cecum adenocarcinoma | Homo sapiens | CVCL_4437 | |
LIM1215 | Colon adenocarcinoma | Homo sapiens | CVCL_2574 | |
HuTu 80 | Duodenal adenocarcinoma | Homo sapiens | CVCL_1301 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
HCT 15 | Colon adenocarcinoma | Homo sapiens | CVCL_0292 | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
GEO | Colon carcinoma | Homo sapiens | CVCL_0271 | |
DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 | |
DiFi | Colorectal carcinoma | Homo sapiens | CVCL_6895 | |
COLO 320DM | Colon adenocarcinoma | Homo sapiens | CVCL_0219 | |
COLO 205 | Colon adenocarcinoma | Homo sapiens | CVCL_0218 | |
Caco-2 | Colon adenocarcinoma | Homo sapiens | CVCL_0025 | |
In-vivo Model | Established subcutaneous xenografts in athymic nude mice with MIR100HGKOE4 CC-CR cells transduced with a luciferase-expressing lentiviral vector and then treated the mice with cetuximab. | |||
Transcription factor ISGF-3 components p91/p84 (Stat1)
In total 3 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [3] | |||
Response Summary | In colorectal cancer, Mettl3- or Mettl14-deficient tumors increased cytotoxic tumor-infiltrating CD8+ T cells and elevated secretion of IFN-gamma, Cxcl9, and Cxcl10 in tumor microenvironment in vivo. Mechanistically, Mettl3 or Mettl14 loss promoted IFN-gamma-Stat1-Irf1 signaling through stabilizing the Transcription factor ISGF-3 components p91/p84 (Stat1) and Irf1 mRNA via Ythdf2. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Down regulation | |||
Pathway Response | PD-L1 expression and PD-1 checkpoint pathway in cancer | hsa05235 | ||
Cell Process | Immunity | |||
In-vitro Model | CT26 | Mouse colon adenocarcinoma | Mus musculus | CVCL_7254 |
B16-GM-CSF (B16-GM-CSF cell line was a kind gift from Drs. Glenn Dranoff and Michael Dougan (Dana-Farber/Harvard Cancer Center)) | ||||
B16-F10 | Mouse melanoma | Mus musculus | CVCL_0159 | |
In-vivo Model | 2 × 106 CT26 cells with knockout of Mettl3, Mettl14, Mettl3/Stat1, Mettl3/Irf1, Mettl14/Stat1, or Mettl14/Irf1 and control were suspended in 200 uL of PBS/Matrigel (Corning) (1:1) and then subcutaneously inoculated into flank of each mouse. | |||
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene | [3] | |||
Response Summary | In colorectal cancer, Mettl3- or Mettl14-deficient tumors increased cytotoxic tumor-infiltrating CD8+ T cells and elevated secretion of IFN-gamma, Cxcl9, and Cxcl10 in tumor microenvironment in vivo. Mechanistically, Mettl3 or Mettl14 loss promoted IFN-gamma-Stat1-Irf1 signaling through stabilizing the Transcription factor ISGF-3 components p91/p84 (Stat1) and Irf1 mRNA via Ythdf2. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 14 (METTL14) | WRITER | ||
Target Regulation | Down regulation | |||
Pathway Response | PD-L1 expression and PD-1 checkpoint pathway in cancer | hsa05235 | ||
Cell Process | Immunity | |||
In-vitro Model | CT26 | Mouse colon adenocarcinoma | Mus musculus | CVCL_7254 |
B16-GM-CSF (B16-GM-CSF cell line was a kind gift from Drs. Glenn Dranoff and Michael Dougan (Dana-Farber/Harvard Cancer Center)) | ||||
B16-F10 | Mouse melanoma | Mus musculus | CVCL_0159 | |
In-vivo Model | 2 × 106 CT26 cells with knockout of Mettl3, Mettl14, Mettl3/Stat1, Mettl3/Irf1, Mettl14/Stat1, or Mettl14/Irf1 and control were suspended in 200 uL of PBS/Matrigel (Corning) (1:1) and then subcutaneously inoculated into flank of each mouse. | |||
Experiment 3 Reporting the m6A-centered Disease Response by This Target Gene | [3] | |||
Response Summary | In colorectal cancer, Mettl3- or Mettl14-deficient tumors increased cytotoxic tumor-infiltrating CD8+ T cells and elevated secretion of IFN-gamma, Cxcl9, and Cxcl10 in tumor microenvironment in vivo. Mechanistically, Mettl3 or Mettl14 loss promoted IFN-gamma-Stat1-Irf1 signaling through stabilizing the Transcription factor ISGF-3 components p91/p84 (Stat1) and Irf1 mRNA via Ythdf2. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Down regulation | |||
Pathway Response | PD-L1 expression and PD-1 checkpoint pathway in cancer | hsa05235 | ||
Cell Process | Immunity | |||
In-vitro Model | CT26 | Mouse colon adenocarcinoma | Mus musculus | CVCL_7254 |
B16-GM-CSF (B16-GM-CSF cell line was a kind gift from Drs. Glenn Dranoff and Michael Dougan (Dana-Farber/Harvard Cancer Center)) | ||||
B16-F10 | Mouse melanoma | Mus musculus | CVCL_0159 | |
In-vivo Model | 2 × 106 CT26 cells with knockout of Mettl3, Mettl14, Mettl3/Stat1, Mettl3/Irf1, Mettl14/Stat1, or Mettl14/Irf1 and control were suspended in 200 uL of PBS/Matrigel (Corning) (1:1) and then subcutaneously inoculated into flank of each mouse. | |||
Transcription factor SOX-2 (SOX2)
In total 2 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [43] | |||
Response Summary | METTL3, acting as an oncogene, maintained Transcription factor SOX-2 (SOX2) expression through an m6A-IGF2BP2-dependent mechanism in CRC cells, and indicated a potential biomarker panel for prognostic prediction in Colorectal carcinoma. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | Signaling pathways regulating pluripotency of stem cells | hsa04550 | ||
Cell Process | Cell self-renewal | |||
Stem cell frequency | ||||
Cell migration | ||||
In-vitro Model | CCD-112CoN | Normal | Homo sapiens | CVCL_6382 |
DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
HCT 15 | Colon adenocarcinoma | Homo sapiens | CVCL_0292 | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
LS174T | Colon adenocarcinoma | Homo sapiens | CVCL_1384 | |
RKO | Colon carcinoma | Homo sapiens | CVCL_0504 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene | [43] | |||
Response Summary | METTL3, acting as an oncogene, maintained Transcription factor SOX-2 (SOX2) expression through an m6A-IGF2BP2-dependent mechanism in CRC cells, and indicated a potential biomarker panel for prognostic prediction in Colorectal carcinoma. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | Signaling pathways regulating pluripotency of stem cells | hsa04550 | ||
Cell Process | Cell self-renewal | |||
Stem cell frequency | ||||
Cell migration | ||||
In-vitro Model | CCD-112CoN | Normal | Homo sapiens | CVCL_6382 |
DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
HCT 15 | Colon adenocarcinoma | Homo sapiens | CVCL_0292 | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
LS174T | Colon adenocarcinoma | Homo sapiens | CVCL_1384 | |
RKO | Colon carcinoma | Homo sapiens | CVCL_0504 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
Transcription factor SOX-4 (SOX4)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [44] | |||
Response Summary | METTL14 inhibited colorectal cancer malignant process partly through Transcription factor SOX-4 (SOX4)-mediated EMT process and PI3K/Akt signals. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 14 (METTL14) | WRITER | ||
Target Regulation | Down regulation | |||
Pathway Response | PI3K-Akt signaling pathway | hsa04151 | ||
Cell Process | Cell migration | |||
Cell invasion | ||||
Cell metastasis | ||||
In-vitro Model | DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
NCM460 | Normal | Homo sapiens | CVCL_0460 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
In-vivo Model | 2 × 106 transfected HCT116 cells in 0.2 ml PBS were injected into the tail vein of nude mice which were randomly divided into nine groups (eight mice per group). | |||
Transcriptional coactivator YAP1 (YAP1)
In total 2 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [35] | |||
Response Summary | IGF2BP2 activates the expression of ErbB2 by recognizing the m6A of Transcriptional coactivator YAP1 (YAP1), thus affecting the cell cycle of colorectal cancer, inhibiting cell apoptosis, and promoting proliferation. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Responsed Drug | Temozolomide | Approved | ||
Target Regulator | Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | Hippo signaling pathway | hsa04390 | ||
Cell Process | Cell apoptosis | |||
In-vitro Model | HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
In-vivo Model | IGF2BP2 activates the expression of ErbB2 by recognizing the m6A of YAP, thus affecting the cell cycle of CRC, inhibiting cell apoptosis, and promoting proliferation. | |||
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene | [22] | |||
Response Summary | METTL3-induced circ1662 promoted colorectal cancer cell invasion and migration by accelerating Transcriptional coactivator YAP1 (YAP1) nuclear transport. Circ1662 enhanced CRC invasion and migration depending on YAP1 and SMAD3. This result implies that circ1662 is a new prognostic and therapeutic marker for CRC metastasis. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | Hippo signaling pathway | hsa04390 | ||
Cell Process | Cell invasion | |||
Cell migration | ||||
In-vitro Model | HEK293T | Normal | Homo sapiens | CVCL_0063 |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
In-vivo Model | BALB/c nude mice (4 weeks old) were acquired from Vital River Laboratory (Beijing, China). HCT116 cells with stable circ1662 expression (2 × 106 in 100 L of PBS) were injected via the tail vein. After 45 days, the mice were sacrificed. The lung metastatic carcinoma specimens were processed into paraffin-embedded sections for subsequent H&E staining and IHC. | |||
Translocation protein SEC62 (SEC62)
In total 2 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [45] | |||
Response Summary | Translocation protein SEC62 (SEC62) upregulated by the METTL3-mediated m6A modification promotes the stemness and chemoresistance of colorectal cancer by binding to beta-catenin and enhancing Wnt signalling. Depletion of Sec62 sensitized the CRC cells to 5-Fu or oxaliplatin treatment. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Responsed Drug | Fluorouracil | Approved | ||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | Wnt signaling pathway | hsa04310 | ||
Cell Process | Protein degradation | |||
In-vitro Model | DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
In-vivo Model | DLD-1 cells were subcutaneously implanted into 4-6 weeks old female nude mice. When tumors reached a size of about 50 mm3, the nude mice were randomly divided into 6 groups. | |||
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene | [45] | |||
Response Summary | Translocation protein SEC62 (SEC62) upregulated by the METTL3-mediated m6A modification promotes the stemness and chemoresistance of colorectal cancer by binding to beta-catenin and enhancing Wnt signalling. Depletion of Sec62 sensitized the CRC cells to 5-Fu or oxaliplatin treatment. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Responsed Drug | Oxaliplatin | Approved | ||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | Wnt signaling pathway | hsa04310 | ||
Cell Process | Protein degradation | |||
In-vitro Model | DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
In-vivo Model | DLD-1 cells were subcutaneously implanted into 4-6 weeks old female nude mice. When tumors reached a size of about 50 mm3, the nude mice were randomly divided into 6 groups. | |||
Tyrosine-protein kinase EIF2AK2 (eIF2AK2/p68)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [46] | |||
Response Summary | YTHDF3 was highly expressed in oxaliplatin-resistant (OXAR) CRC tissues and cells. YTHDF3 as a novel hallmark and revealed the molecular mechanism of YTHDF3 on gene translation via coordination with Tyrosine-protein kinase EIF2AK2 (eIF2AK2/p68) in OXAR CRC cells. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | YTH domain-containing family protein 3 (YTHDF3) | READER | ||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
Caco-2 | Colon adenocarcinoma | Homo sapiens | CVCL_0025 | |
RKO | Colon carcinoma | Homo sapiens | CVCL_0504 | |
HCoEpiC (Healthy colon epithelial HCoEpiC cells) | ||||
FHC | Normal | Homo sapiens | CVCL_3688 | |
U4/U6 small nuclear ribonucleoprotein Prp31 (PRPF31/RP11)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [7] | |||
Response Summary | The U4/U6 small nuclear ribonucleoprotein Prp31 (PRPF31/RP11)/hnRNPA2B1/mRNA complex accelerated the mRNA degradation of two E3 ligases, Siah1 and Fbxo45, and subsequently prevented the proteasomal degradation of Zeb1. m6A can regulate the expression of RP11, further, RP11 regulated Siah1-Fbxo45/Zeb1 was involved in the development of Colorectal cancer. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | Proteasome | hsa03050 | ||
Cell Process | Proteasomal degradation | |||
In-vitro Model | DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 |
HCT 15 | Colon adenocarcinoma | Homo sapiens | CVCL_0292 | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
RKO | Colon carcinoma | Homo sapiens | CVCL_0504 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
In-vivo Model | HCT-15 RP11 stable overexpression or control cells (2 × 106 per mouse) diluted in 100 uL normal medium + 100 uL Matrigel (BD Biosciences) were subcutaneously injected into immunodeficient mice to investigate tumour growth. | |||
Urokinase-type plasminogen activator (PLAU)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [47] | |||
Response Summary | METTL3 upregulated Urokinase-type plasminogen activator (PLAU) mRNA in an m6A-dependent manner, and then participated in MAPK/ERK pathway to promote angiogenesis and metastasis in CRC. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
In-vitro Model | LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
In-vivo Model | 1 × 106 cells in 100 uL PBS (shMETTL3-1 or shNC) were respectively injected into each mouse through the tail vein. Pulmonary metastases were monitored after fourteen days using the imaging system (IVIS) Spectrum (PerkinElmer, USA). | |||
Vascular endothelial growth factor A (VEGFA)
In total 3 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [8] | |||
Response Summary | EphA2 and Vascular endothelial growth factor A (VEGFA) targeted by METTL3 via different IGF2BP-dependent mechanisms were found to promote vasculogenic mimicry (VM) formation via PI3K/AKT/mTOR and ERK1/2 signaling in CRC. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Pathway Response | PI3K-Akt signaling pathway | hsa04151 | ||
In-vitro Model | SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
NCM460 | Normal | Homo sapiens | CVCL_0460 | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 | |
In-vivo Model | A total of 8 × 106 wild-type (WT) or METTL3-knockdown cells were injected into the dorsal flanks of 6-week-old nude mice. Seven mice were randomly selected to calculate the volume according to the following formula: V = (width2 × length)/2. Mice were euthanized three weeks after injection and tumors removed, weighed, fixed, and embedded for immunohistochemical analysis. | |||
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene | [8] | |||
Response Summary | EphA2 and Vascular endothelial growth factor A (VEGFA) targeted by METTL3 via different IGF2BP3-dependent mechanisms were found to promote vasculogenic mimicry (VM) formation via PI3K/AKT/mTOR and ERK1/2 signaling in CRC. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | PI3K-Akt signaling pathway | hsa04151 | ||
In-vitro Model | SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
NCM460 | Normal | Homo sapiens | CVCL_0460 | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 | |
In-vivo Model | A total of 8 × 106 wild-type (WT) or METTL3-knockdown cells were injected into the dorsal flanks of 6-week-old nude mice. Seven mice were randomly selected to calculate the volume according to the following formula: V = (width2 × length)/2. Mice were euthanized three weeks after injection and tumors removed, weighed, fixed, and embedded for immunohistochemical analysis. | |||
Experiment 3 Reporting the m6A-centered Disease Response by This Target Gene | [8] | |||
Response Summary | EphA2 and Vascular endothelial growth factor A (VEGFA) targeted by METTL3 via different IGF2BP2-dependent mechanisms were found to promote vasculogenic mimicry (VM) formation via PI3K/AKT/mTOR and ERK1/2 signaling in CRC. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | PI3K-Akt signaling pathway | hsa04151 | ||
In-vitro Model | SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
NCM460 | Normal | Homo sapiens | CVCL_0460 | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 | |
In-vivo Model | A total of 8 × 106 wild-type (WT) or METTL3-knockdown cells were injected into the dorsal flanks of 6-week-old nude mice. Seven mice were randomly selected to calculate the volume according to the following formula: V = (width2 × length)/2. Mice were euthanized three weeks after injection and tumors removed, weighed, fixed, and embedded for immunohistochemical analysis. | |||
Wee1-like protein kinase (WEE1)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [48] | |||
Response Summary | KIAA1429 plays an oncogenic role in CRC cells by inhibiting the expression of Wee1-like protein kinase (WEE1) in an m6A-independent manner and is associated with poor survival in CRC patients. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulation | Down regulation | |||
Zinc finger E-box-binding homeobox 1 (ZEB1)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [7] | |||
Response Summary | The RP11/hnRNPA2B1/mRNA complex accelerated the mRNA degradation of two E3 ligases, Siah1 and Fbxo45, and subsequently prevented the proteasomal degradation of Zinc finger E-box-binding homeobox 1 (ZEB1). m6A can regulate the expression of RP11, further, RP11 regulated Siah1-Fbxo45/Zeb1 was involved in the development of Colorectal cancer. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | Proteasome | hsa03050 | ||
Cell Process | Proteasomal degradation | |||
In-vitro Model | DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 |
HCT 15 | Colon adenocarcinoma | Homo sapiens | CVCL_0292 | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
RKO | Colon carcinoma | Homo sapiens | CVCL_0504 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
In-vivo Model | HCT-15 RP11 stable overexpression or control cells (2 × 106 per mouse) diluted in 100 uL normal medium + 100 uL Matrigel (BD Biosciences) were subcutaneously injected into immunodeficient mice to investigate tumour growth. | |||
Zinc finger protein SNAI1 (SNAI1)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [49] | |||
Response Summary | METTL3 acts as a critical m6A methyltransferase capable of facilitating colorectal cancer(CRC) progression, and revealed a novel mechanism by which METTL3 promotes CRC cell proliferation and invasion via stabilizing Zinc finger protein SNAI1 (SNAI1) mRNA in an m6A-dependent manner. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | Adherens junction | hsa04520 | ||
Cell Process | Cell proliferation | |||
Cell invasion | ||||
In-vitro Model | SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 |
NCM460 | Normal | Homo sapiens | CVCL_0460 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
HIEC-6 | Normal | Homo sapiens | CVCL_6C21 | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
Growth arrest specific 5 (GAS5)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [50] | |||
Response Summary | A new mechanism for m6A-induced decay of Growth arrest specific 5 (GAS5) on YAP signaling in progression of Colorectal cancer which offers a promising approach for CRC treatment. LncRNA GAS5 expressions is negatively correlated with YAP and YTHDF3 protein levels in tumors from CRC patients. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | YTH domain-containing family protein 3 (YTHDF3) | READER | ||
Target Regulation | Down regulation | |||
Pathway Response | Hippo signaling pathway | hsa04390 | ||
Cell Process | Ubiquitination degradation | |||
In-vitro Model | DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
LS174T | Colon adenocarcinoma | Homo sapiens | CVCL_1384 | |
RKO | Colon carcinoma | Homo sapiens | CVCL_0504 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
LBX2 antisense RNA 1 (LBX2-AS1)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [51] | |||
Response Summary | The increased LBX2 antisense RNA 1 (LBX2-AS1) in CRC was mediated by METTL3-dependent m6A methylation. LBX2-AS1 serves as a therapeutic target and predictor of 5-FU benefit in colorectal cancer patients. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Responsed Drug | Fluorouracil | Approved | ||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Long intergenic non-protein coding RNA 2598 (LINC02598/RP11)
In total 2 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [52] | |||
Response Summary | Overexpression of METTL3 upregulates Long intergenic non-protein coding RNA 2598 (LINC02598/RP11) expression in colorectal cancer cells. Overexpression of ALKBH5 downregulates RP11 expression. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | RNA demethylase ALKBH5 (ALKBH5) | ERASER | ||
Target Regulation | Down regulation | |||
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene | [52] | |||
Response Summary | Overexpression of METTL3 upregulates Long intergenic non-protein coding RNA 2598 (LINC02598/RP11) expression in colorectal cancer cells. Overexpression of ALKBH5 downregulates RP11 expression. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | Ubiquitin mediated proteolysis | hsa04120 | ||
Cell Process | Ubiquitination degradation | |||
In-vitro Model | HCT 15 | Colon adenocarcinoma | Homo sapiens | CVCL_0292 |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
NCM460 | Normal | Homo sapiens | CVCL_0460 | |
Long intergenic non-protein coding RNA 460 (LINC00460)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [17] | |||
Response Summary | Long intergenic non-protein coding RNA 460 (LINC00460) is a novel oncogene of colorectal cancer through interacting with IGF2BP2 and DHX9 and bind to the m6A modified HMGA1 mRNA to enhance the HMGA1 mRNA stability. The N6-methyladenosine (m6A) modification of HMGA1 mRNA by METTL3 enhanced HMGA1 expression in CRC. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | mRNA surveillance pathway | hsa03015 | ||
Cell Process | mRNA stability | |||
Epithelial-mesenchymal transition | ||||
In-vitro Model | DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 |
FHC | Normal | Homo sapiens | CVCL_3688 | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
In-vivo Model | Groups of HCT116-Luc-shCtrl, HCT116-Luc-shLINC00460, and HCT116-Luc-shLINC00460 + HMGA1 cells (5 × 106) were injected subcutaneously into the flanks of mice correspondingly. | |||
Nuclear paraspeckle assembly transcript 1 (NEAT1)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [53] | |||
Response Summary | ALKBH5 knockdown suppressed malignant behavior of colon cancer partially through Nuclear paraspeckle assembly transcript 1 (NEAT1) by demethylation in vitro and vivo, suggesting that ALKBH5-NEAT1 axis is a potential therapeutic target for colon cancer treatment. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | RNA demethylase ALKBH5 (ALKBH5) | ERASER | ||
Target Regulation | Up regulation | |||
Cell Process | Cell proliferation and migration | |||
Cell apoptosis | ||||
In-vitro Model | HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 |
HIEC (Normal intestinal epithelial cells) | ||||
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
RKO | Colon carcinoma | Homo sapiens | CVCL_0504 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
In-vivo Model | To establish xenograft model, RKO cells (1 × 107) tansduced with si-control (si-NC) or si-ALKBH5 or si-ALKBH5+NEAT1 were injected subcutaneously into the right flank of the nude mice (n = 6 each group) every 5 days for 4 times. | |||
X inactive specific transcript (XIST)
In total 2 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [54] | |||
Response Summary | In colorectal cancer, knockdown of METTL14 substantially abolished m6A level of X inactive specific transcript (XIST) and augmented XIST expression. m6A-methylated XIST was recognized by YTHDF2, a m6A reader protein, to mediate the degradation of XIST. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Down regulation | |||
Cell Process | Tumorigenicity and metastasis | |||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
NCM460 | Normal | Homo sapiens | CVCL_0460 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
In-vivo Model | For liver metastasis model, mice were anaesthetized and an incision was made through the skin and peritoneum to expose the spleen. 1 × 106 HCT116 cells were injected into the spleen (n = 4 each group). | |||
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene | [54] | |||
Response Summary | In colorectal cancer, knockdown of METTL14 substantially abolished m6A level of X inactive specific transcript (XIST) and augmented XIST expression. m6A-methylated XIST was recognized by YTHDF2, a m6A reader protein, to mediate the degradation of XIST. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 14 (METTL14) | WRITER | ||
Target Regulation | Up regulation | |||
Cell Process | Tumorigenicity and metastasis | |||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
NCM460 | Normal | Homo sapiens | CVCL_0460 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
In-vivo Model | For liver metastasis model, mice were anaesthetized and an incision was made through the skin and peritoneum to expose the spleen. 1 × 106 HCT116 cells were injected into the spleen (n = 4 each group). | |||
ZNFX1 antisense RNA 1 (ZFAS1)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [30] | |||
Response Summary | The critical modulation network underlying m6A readers stabilizes lncRNAs, and they jointly promote mitochondrial energy metabolism in the pathogenesis of colorectal cancer. N6-methyladenosine reader stabilizes the ZFAS1/OLA1 axis. Thus, direct interaction between the KH3-4 domain of IMP2 and ZFAS1 where IMP2 serves as a reader for m6A-modified ZFAS1 and promotes the RNA stability of ZFAS1 is critical for CRC development. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) | READER | ||
Target Regulation | Up regulation | |||
Cell Process | Warburg effect | |||
Mitochondrial energy metabolism | ||||
In-vitro Model | Caco-2 | Colon adenocarcinoma | Homo sapiens | CVCL_0025 |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
HIEC (Normal intestinal epithelial cells) | ||||
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
RKO | Colon carcinoma | Homo sapiens | CVCL_0504 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
microRNA 1246 (MIR1246)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [39] | |||
Response Summary | METTL3/microRNA 1246 (MIR1246)/SPRED2 axis plays an important role in tumor metastasis and provides a new m6A modification pattern in Colorectal cancer development. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
Cell Process | Cell migration and invasion | |||
In-vitro Model | Caco-2 | Colon adenocarcinoma | Homo sapiens | CVCL_0025 |
DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
NCM460 | Normal | Homo sapiens | CVCL_0460 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
In-vivo Model | The spleen in the upper left lateral abdomen of the anesthetized mice were exposed, 106 cells suspended in 20 uL phosphate-buffered saline (PBS) were injected into the distal tip of the spleen. After injection, replacing the spleen, and closing the incision. | |||
microRNA 21 (MIR21)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [11] | |||
Response Summary | ALKBH5 plays an antitumor role in colorectal cancer by modulating the FOXO3/microRNA 21 (MIR21)/SPRY2 axis, which not only suggests a regulatory effect between ALKBH5 and FOXO3, but also provides a new therapeutic direction for colorectal cancer. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | RNA demethylase ALKBH5 (ALKBH5) | ERASER | ||
Pathway Response | FoxO signaling pathway | hsa04068 | ||
In-vitro Model | Caco-2 | Colon adenocarcinoma | Homo sapiens | CVCL_0025 |
FHC | Normal | Homo sapiens | CVCL_3688 | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
microRNA 375 (MIR375)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [55] | |||
Response Summary | METTL14 suppressed Colorectal cancer cell growth, migration, and invasion via the microRNA 375 (MIR375)/YAP1 and miR-375/SP1 pathways. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 14 (METTL14) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | Hippo signaling pathway | hsa04390 | ||
Cell Process | Cell growth and metastasis | |||
In-vitro Model | DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 |
FHC | Normal | Homo sapiens | CVCL_3688 | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
In-vivo Model | Six-week-old BALB/c nude mice were purchased from the College of Veterinary Medicine, Yang Zhou University. For the xenografted tumor model, 1 × 107 HCT116 cells in 0.2 mL PBS were subcutaneously injected into BALB/c nude mice, which were randomly divided into four groups (six mice per group). The volume of the tumors was calculated with the following equation: V = 0.5 × (length × width2). For metastasis experiments, 2 × 106 cells in 0.2 mL PBS were injected into the tail vein of nude mice, which were randomly divided into four groups (six mice per group). | |||
Mir-100-let-7a-2-mir-125b-1 cluster host gene (MIR100HG)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [42] | |||
Response Summary | Mir-100-let-7a-2-mir-125b-1 cluster host gene (MIR100HG) and hnRNPA2B1 interact to control the transcriptional activity of Wnt signaling in CRC via regulation of TCF7L2 mRNA stability. These findings identified MIR100HG as a potent EMT inducer in CRC that will contribute to cetuximab resistance and metastasis by activation of a MIR100HG/hnRNPA2B1/TCF7L2 feedback loop. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Responsed Drug | Cetuximab | Approved | ||
Target Regulator | Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | Wnt signaling pathway | hsa04310 | ||
Cell Process | Epithelial-mesenchymal transition | |||
In-vitro Model | VACO 9P | Rectal adenocarcinoma | Homo sapiens | CVCL_5413 |
T84 | Colon adenocarcinoma | Homo sapiens | CVCL_0555 | |
SW948 | Colon adenocarcinoma | Homo sapiens | CVCL_0632 | |
SW837 | Rectal adenocarcinoma | Homo sapiens | CVCL_1729 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW48 | Colon adenocarcinoma | Homo sapiens | CVCL_1724 | |
SW403 | Colon adenocarcinoma | Homo sapiens | CVCL_0545 | |
SW1116 | Colon adenocarcinoma | Homo sapiens | CVCL_0544 | |
SK-CO-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0626 | |
RKO | Colon carcinoma | Homo sapiens | CVCL_0504 | |
NCI-H716 | Cecum adenocarcinoma | Homo sapiens | CVCL_1581 | |
NCI-H508 | Cecum adenocarcinoma | Homo sapiens | CVCL_1564 | |
LS174T | Colon adenocarcinoma | Homo sapiens | CVCL_1384 | |
LS123 | Colon adenocarcinoma | Homo sapiens | CVCL_1383 | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
LIM2405 | Cecum adenocarcinoma | Homo sapiens | CVCL_4437 | |
LIM1215 | Colon adenocarcinoma | Homo sapiens | CVCL_2574 | |
HuTu 80 | Duodenal adenocarcinoma | Homo sapiens | CVCL_1301 | |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
HCT 15 | Colon adenocarcinoma | Homo sapiens | CVCL_0292 | |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
GEO | Colon carcinoma | Homo sapiens | CVCL_0271 | |
DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 | |
DiFi | Colorectal carcinoma | Homo sapiens | CVCL_6895 | |
COLO 320DM | Colon adenocarcinoma | Homo sapiens | CVCL_0219 | |
COLO 205 | Colon adenocarcinoma | Homo sapiens | CVCL_0218 | |
Caco-2 | Colon adenocarcinoma | Homo sapiens | CVCL_0025 | |
In-vivo Model | Established subcutaneous xenografts in athymic nude mice with MIR100HGKOE4 CC-CR cells transduced with a luciferase-expressing lentiviral vector and then treated the mice with cetuximab. | |||
hsa-miR-181d-5p
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [29] | |||
Response Summary | METTL3?dependent m6A methylation was upregulated in CRC to promote the processing of miR?181d?5p by DGCR8. This led to increased hsa-miR-181d-5p expression, which inhibited the 5?FU sensitivity of CRC cells by targeting NCALD. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Responsed Drug | Fluorouracil | Approved | ||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
In-vitro Model | HT29 | Colon cancer | Mus musculus | CVCL_A8EZ |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
In-vivo Model | A tumor-bearing model was established by subcutaneously injecting 100 ul HT29 cells (5×106) followed by an intravenous injection of CAFs-derived exosomes (50 ug/mouse every three days) into the tail vein of the mice. An intraperitoneal injection of 5-FU (50 mg/kg, every week) was administered on day 12. | |||
hsa_circ_0000677
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [56] | |||
Response Summary | hsa_circ_0000677 and its downstream target ABCC1 were upregulated in CRC cells, induced by the METTL3-mediated m6 A modification of circ_0000677 and SUMO1-mediated SUMOylation of METTL3. This work provided a new strategy for the therapeutic treatment of CRC. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
In-vitro Model | NCM460 | Normal | Homo sapiens | CVCL_0460 |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
HCT 15 | Colon adenocarcinoma | Homo sapiens | CVCL_0292 | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
Caco-2 | Colon adenocarcinoma | Homo sapiens | CVCL_0025 | |
In-vivo Model | For the tumor xenograft, mice were randomly divided into three groups with four mice for each group. Then, 1 × 106 cells after indicated treatment were harvested and resuspended in 50 ul of PBS. Then the cells were subcutaneously injected into the right front flank of each mouse. | |||
Circ_1662
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [22] | |||
Response Summary | METTL3-induced Circ_1662 promoted colorectal cancer cell invasion and migration by accelerating YAP1 nuclear transport. Circ1662 enhanced CRC invasion and migration depending on YAP1 and SMAD3. This result implies that circ1662 is a new prognostic and therapeutic marker for CRC metastasis. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | Hippo signaling pathway | hsa04390 | ||
Cell Process | Cell invasion | |||
Cell migration | ||||
In-vitro Model | HEK293T | Normal | Homo sapiens | CVCL_0063 |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
In-vivo Model | BALB/c nude mice (4 weeks old) were acquired from Vital River Laboratory (Beijing, China). HCT116 cells with stable circ1662 expression (2 × 106 in 100 L of PBS) were injected via the tail vein. After 45 days, the mice were sacrificed. The lung metastatic carcinoma specimens were processed into paraffin-embedded sections for subsequent H&E staining and IHC. | |||
References